Vertex responds to NHS’s ‘final’ offer

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it is evaluating a “final” offer from NHS England for the company’s cystic fibrosis drugs but is concerned the latest bid to break the stalemate between the parties falls short.

Under the

Read the full 362 word article

User Sign In